SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

US ETFDetailed Quotes

XBI SPDR S&P Biotech ETF

Watchlist

97.420
-0.820-0.83%

Close Dec 10 16:00 ET

98.610High97.100Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BofA Restarts Coverage of 11 Large-cap Biopharmas
Seeking Alpha17:01 ET
Market Falls Wednesday, but Googles Chip Impresses | WST
Kevin Travers16:19 ET
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga12:35 ET
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Kevin TraversDec 10 10:51 ET
Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024
BenzingaDec 10 10:30 ET
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
BenzingaDec 10 07:24 ET · Ratings

Comments

topcing

Nov 4 21:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?